Navigating the challenges of mass vaccine production
New opinion piece from Watson-Marlow Fluid Technology Group launched today.
Falmouth, UK, 28th September 2020 / Sciad Newswire / Watson-Marlow Fluid Technology Group (WMFTG) launches a new article discussing the challenges of rapidly scaling up vaccine production to meet global demands.
The opinion piece looks at the significant progress being made in the development of novel vaccine candidates for SARS-CoV-2, shortening development timelines from years to months. Exploring the challenges that remain to scale up production to billions of doses worldwide, experts present their view on the innovation and collaboration needed from the bioprocessing industry to reach this target and the WMFTG technologies currently being used in the process.
In light of the COVID-19 pandemic and the need for a vaccine, biopharmaceutical processing experts have had to adapt technologies to accelerate the vaccine development process and step up manufacturing rapidly from small scale research to clinical trials, and on to widespread production. Knowledge transfer from adjacent fields, such as gene therapy, is vital in order to overcome this new challenge. The use of validated, single-use technologies will be essential to scale efficiently whilst maintaining product quality and satisfying regulatory requirements.
The new article is authored by bioprocessing experts from WMFTG; Jim Sanford, Dr Sade Mokuolu and Peter Birch, with insights from Cobra Biologics’ Technical Director, Tony Hitchcock.
“The technology must be the same in every manufacturing site, that’s how we will achieve process validation and meet the regulatory standards,” commented Tony. “Hopefully, these collaborations will create something truly ground-breaking, based on the very real and solid foundation of tried and test technology.”
The huge leaps being taken to accelerate vaccine production, intensify processes and scale-out production will set the scene for even greater development in these areas. Learn more from the report’s authors in a recent webinar which is available to view now or download the article to hear more from these experts as they provide their unique perspectives on scaling up vaccine manufacturing.
For further information, contact:
Joanne Lucas, Group Marketing PR Coordinator
Watson-Marlow Fluid Technology Group
T: +44 (0) 1326 370 214
Juliette Craggs / Deborah Cockerill / Katie Warren
Sciad Communications Ltd
T: +44 (0)20 3405 7892
Notes to Editors
About Watson-Marlow Fluid Technology Group
Watson-Marlow Fluid Technology Group is part of Spirax-Sarco Engineering plc, a FTSE 100 company. The company is an award-winning, global leader in fluid management technology and for over 60 years has engineered components and systems for customers in a wide range of pharmaceutical and industrial markets. Learn more at www.wmftg.com or @WMFTG_news.
Got an innovation you need bringing to life?
We’d love to hear from you! Head to our contact page to start a conversation.